Uses

Proteasome inhibitor indicated for treatment of relapsed or refractory multiple myeloma in adults, either alone or in combination regimens.

Do not use if

No specific contraindications are listed in approved labeling.

Side effects

Serious adverse effects include cardiac toxicity, renal failure, pulmonary complications, tumor lysis syndrome, and hypertension. Fatigue, anemia, and infections may also occur.

Warnings

Monitor for cardiac events, renal dysfunction, pulmonary toxicity, and tumor lysis syndrome during treatment.

How it works

Carfilzomib irreversibly inhibits the 20S proteasome, leading to accumulation of proteins and apoptosis of malignant plasma cells.

Storage

Store unopened vials refrigerated at 2–8°C in the original package protected from light.